Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane 2015
Related articles (Crohn):
*Methotrexate in Crohn
*Infliximab in Crohn (ACCENT I)
*Infliximab with Azathiopurine (Crohn)
*Infliximab with Methotrexate (Crohn)
*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)
*Adalimumab (CLASSIC & CHARM trial – Crohn)
*Adalimumab with immunomodulator (Crohn)
*Ustekinumab (UNITI trial – Crohn – 2016)
*Vedolizumab (GEMINI II – Crohn – 2013)
Related articles (Azathioprine):
*Infliximab with Azathiopurine (Ulcerative Colitis)
*Thiopurine metabolite monitoring
*Proctitis: Azathiopurine
Authors’ conclusions: Low quality evidence suggests that AZA is more effective than placebo for maintenance of remission in Crohn’s disease. Although AZA may be effective for maintenance of remission its use is limited by adverse effects. Low quality evidence suggests that AZA may be superior to budesonide for maintenance of remission but because of small study size and high risk of bias, this result should be interpreted with caution. No conclusions can be drawn from the other active comparator studies because of low and very low quality evidence. Adequately powered trials are needed to determine the comparative efficacy and safety of AZA and 6-MP compared to other active maintenance therapies. Further research is needed to assess the efficacy and safety of the use of AZA with infliximab and other biologics and to determine the optimal management strategy for patients quiescent Crohn’s disease.
References:
Recent Comments